The article mentions that Lifecore Biomedical has received 4 somewhat bullish and 1 indifferent analyst ratings in the last quarter. The average 12-month price target is $7.8, which is a 20% decrease from the previous average of $9.75. This indicates that analysts are not extremely bullish on the stock, but they are not bearish either. Therefore, the short-term impact on the stock price is likely to be neutral.